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background: Colchicine has been suggested to be beneficial in preventing recurrent pericarditis. The goal of this study was to review all 
randomized controlled trials that assess the effects of colchicine to prevent recurrence of pericarditis or post-pericardiotomy syndrome.
Methods: We performed a meta-analysis of the effect of colchicine versus conventional treatment on pericarditis recurrence, medication 
discontinuation and adverse events. We conducted an EMBASE and MEDLINE search for prospective randomized, controlled trials .
Results: We identified 7 prospective randomized studies with 809 patients in the colchicine group and 826 in the conventional treatment 
group. Our analysis showed that colchicine is associated with reduced risk of pericarditis recurrence, with homogenous results across three 
clinical settings (Figure). However, mainly driven by the results of the COPPS-2 trial colchicine was associated with more adverse events 
and higher rates of discontinuation in the post-pericardiotmy subgroup analysis. Colchicine was not associated with significantly higher 
rates of adverse events and drug withdrawals when used for secondary prevention of pericarditis. Diarrhea was the main adverse event of 
colchicine.
 
conclusion:  Colchicine appears to be efficacious and well tolerated for recurrent pericarditis and should be considered a first-line agent. 
However, its efficacy post-cardiac surgery is limited by adverse events .
